A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Summary

The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

Timeline

Start

2023-02-07

Primary completion

2025-05-02

Completion

2026-10-23

Drugs

Indications